Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more
than two decades without clinical progress, the addition of programmed cell death protein 1 …

Highlights•ICIs have shifted the treatment paradigm to improve overall survival in advanced
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …

Background In the phase III CASPIAN study, first-line durvalumab in combination with
etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival …

Abstract Objectives In the Phase I/III IMpower133 study, first-line atezolizumab plus
carboplatin and etoposide (CP/ET) treatment for extensive-stage small cell lung cancer (ES …

Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly
poor prognosis. For decades, the best available systemic therapy was platinum plus …

Background Delta-like ligand 3 (DLL3) is a therapeutic target in small-cell lung cancer
(SCLC). However, how DLL3 expression status affects the tumor microenvironment (TME) …

Background The current standard treatment for limited-stage small-cell lung cancer (LS-
SCLC) is chemotherapy with concurrent chemoradiotherapy (CCRT). Methods In this single …

Abstract Introduction In the phase 1/3 IMpower133 study, atezolizumab plus carboplatin and
etoposide (CP/ET) followed by maintenance atezolizumab for first-line treatment of extensive …

Highlights•The addition of PD-L1 inhibitors but not CTLA-4 inhibitors to platinum/etoposide
improves survival in first line SCLC.•A small proportion of patients derive long-term survival …

Introduction Small cell lung cancer (SCLC) is an aggressive tumor with a severe prognosis.
At the time of diagnosis, most patients present with extensive-stage (ES) disease. For …